Amneal Secures FDA Approval for Romidepsin Injection, Gaining 180-Day Exclusivity

Why It Matters

The approval expands treatment options for patients with cutaneous T‑cell lymphoma, a disease where therapeutic choices are scarce after first‑line regimens fail. By re‑introducing romidepsin in a ready‑to‑use format, Amneal addresses a practical barrier that has limited the drug’s use since its withdrawal, potentially improving outcomes for a vulnerable patient cohort. For the pharmaceutical industry, the CGT designation illustrates how companies can leverage regulatory pathways to secure short‑term exclusivity for reformulated products. This case may encourage other generic manufacturers to revisit withdrawn or off‑patent therapies, repackaging them to meet modern clinical and logistical needs while extracting incremental value before full generic competition arrives.

Key Takeaways

• Amneal received FDA approval for a 27.5 mg/5.5 mL romidepsin injection solution on June 5, 2026.
• The drug is indicated for cutaneous T‑cell lymphoma in adults who have received at least one prior systemic therapy.
• Competitive Generic Therapy status grants Amneal 180 days of market exclusivity.
• Amneal’s Nasdaq share price rose 2.45% to $13.19 following the announcement.
• The product revives a former Teva formulation that was withdrawn years earlier.

Pulse Analysis

Amneal’s FDA win signals a broader shift among generic firms toward specialty reformulations as a growth engine. Traditional volume‑driven generic business models are under pressure from price erosion and aggressive competition, prompting companies to seek higher‑margin niches. By securing a CGT designation, Amneal can monetize a legacy molecule without the extensive R&D costs of a novel drug, leveraging existing safety data while differentiating on delivery.

Historically, the HDAC inhibitor class has faced mixed commercial success due to toxicity concerns and complex administration. Amneal’s ready‑to‑use vial mitigates some of these hurdles, positioning the product as a more convenient option for oncology infusion centers. If the therapy gains rapid formulary acceptance, the 180‑day exclusivity could translate into several tens of millions in revenue, a meaningful contribution for a company whose 2025 revenue was roughly $1.2 billion.

Looking forward, the real test will be Amneal’s ability to expand romidepsin’s label or develop combination regimens that broaden its market. Success could inspire a wave of similar strategies—reviving withdrawn drugs with modern formulations—to capture value in other rare‑cancer segments. Conversely, if reimbursement proves challenging or safety signals emerge, the upside may be limited. Investors and competitors will monitor launch metrics closely, as they will set the tone for how quickly the CGT pathway becomes a mainstream tool for generic innovators.